Please assess the completion status of the following clinical trial:

Trial Title: 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cases fulfilling WHO (World Health Organization) 2016 diagnostic criteria for MPN including: Chronic myeloid leukemia, BCR-ABL1-positive (BCR-ABL = fusion gene from BCR (breakpoint cluster region gene/BCR gene product), Chronic neutrophilic leukemia (CNL), Polycythemia vera, Primary myelofibrosis prefibrotic/early stage, Primary myelofibrosis overt fibrotic stage, Essential thrombocythemia, Chronic eosinophilic leukemia, not otherwise specified (NOS) and Myeloproliferative neoplasm, unclassifiable.~* Age between 14 and 18 years old~* Patient accepts to sign inform consent~* ECOG (Eastern Cooperative Oncology Group) performance less than or equal 2~Exclusion Criteria:~* Patient not fulfilling the inclusion criteria.~* Vulnerable groups: pregnant, minors, prisoners will not be included.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 18F-FLT PET/CT (Type: EXPERIMENTAL): Patients undergo 18F-FLT (3'-18Fluoro-3'-deoxy-Lthymidine) PET/CT (Positron Emission Tomography/ Computed Tomography) at baseline. No specific dietary restrictions or hydration are required for FLT-PET scans, however, patients will be urged to drink plenty of water before and after the PET studies. \[18F\] FLT will be prepared by the cyclotron core facility and assessed for quality control following good manufacturing practice criteria. The radiopharmaceutical will immediately be brought to the Molecular Imaging and Therapy Service Radiopharmacy for dispensation in the PET suite. For each scan, patients will receive approximately up to 370 MBq (target of 10 mCi) \[18F\] FLT by intravenous infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).